Validation of the French Adaptation of the RAADS-R Scale : Scale of Asperger Syndrome Diagnosis

NCT ID: NCT02826148

Last Updated: 2016-07-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

324 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-12-31

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The diagnosis of developmental disorders in adults is still difficult. Indeed, in France, there is not questionnaires to easily and accurately diagnose this disorder. Several diagnostic scales were developed in English. Among them, RAADS-R scale, which is a clinical tool that aims to better identify autism spectrum disorders including mild forms in adult people and help to diagnose of high-functioning autism . The objective of this study is to perform a complete validation of this scale in the french version.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The diagnosis of developmental disorders in adults is still difficult. Indeed, in France, there is not questionnaires to easily and accurately diagnose this disorder. Several diagnostic scales were developed in English. Among them, RAADS-R scale, which is a clinical tool that aims to better identify autism spectrum disorders including mild forms in adult people and help to diagnose of high-functioning autism . This scale is a self-administered questionnaire completed by the person himself assisted by a clinician (psychiatrist, psychologist) which ensures the understanding of issues and the choice of answers. The scale contains 80 items including 64 questions describe specific symptoms of autism spectrum disorders and 16 questions describe non-symptomatic behaviors. The objective of this study is to perform a complete validation of this scale in the french version. 300 adults should be included, including 100 adults with high-functioning autism, 100 adults with another psychiatric disorder, and 100 adults without developmental disabilities and / or mental.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Autism Spectrum Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with autism disorder

The RAADS-R scale is a self-administered questionnaire completed by the patient himself assisted by a clinician

Group Type OTHER

RAADS-R scale

Intervention Type OTHER

This scale is a self-administered questionnaire completed by the person himself assisted by a clinician

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RAADS-R scale

This scale is a self-administered questionnaire completed by the person himself assisted by a clinician

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Non-specific criteria
* Collection of the informed consent (patient or legal representant)
* Affiliation or recipient with the mode of social security
* Current reading skills evaluated by completion of the fact sheet attached to the scale
* Age limits to \> 18 years and \< 75 years

Specific criteria

* Group of adult subjects with autism

* Diagnosis of autism or Asperger syndrome established within the framework of a multidisciplinary evaluation (ADOS module 4 and/or ADI) using specific international classification criteria of rare diseases (CIM 10, DSM IV-R) (F84.0 et F84.5).
* Intellectual efficiency estimated by means of a psychometric tool standardized (WAIS, WASI) greater than or equal to 85
* Subjects not denying their symptoms
* Group of adult subjects with other psychiatric

* Diagnosis of an other psychiatric trouble established according to the specific international classification criteria of mental diseases (CIM 10, DSM IV).
* absence of pervasive developmental disorder diagnosis
* Subjects not denying their symptoms
* Group of adult subjects not carriers of development and/or psychiatric disorders

Exclusion Criteria

* Women pregnant and Breast-feeding
* Persons deprived of freedom by court order

Specific criteria

* Group of adult subjects with autism

* Refusal of participation
* absence of autism or Asperger syndrome diagnosis
* Group of adult subjects with other psychiatric

* Refusal of participation
* Pervasive developmental disorder diagnosis
* Group of adult subjects not carriers of development and/or psychiatric disorders

* Refusal of participation
* Diagnosis of cognitive development or psychomotor disorder, diagnosis of retard mental and/or psychiatric disorder.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Fondation Orange

UNKNOWN

Sponsor Role collaborator

University Hospital, Montpellier

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Amaria BAGHDADLI, MD-PhD

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Montpellier

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

8747

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.